Protecting Patients and the Responsibilities of the MA Holder

When new information regarding the risks and benefits of a product is established after a Pharmacovigilance investigation, it is prudent that changes are made to the safety information of that product. Patient Information Leaflets must be updated for Health Care Professionals and patients in order to use or prescribe the product safely.

Cannabidiol and Clobazam

Cannabidiol and Clobazam

Cannabidiol and Clobazam can be prescribed to treat paediatric patients with seizures associated with Dravets or Lennox-Gastaut syndromes The latest guidance from National Institute for Health and Care Excellence “NICE”

Manufacturers, Wholesalers, Responsible Persons and Healthcare Professionals must consider how they communicate and what are the effective channels of communication they should consider to effectively get their message across.

The way the public is influenced is aided by technologies which facilitate messages to be spread at speed, and people trust the medias and or people who deliver the message often without question. They often sign up to follow their newfound friend who is now their trusted expert. People join groups and sign up to blogs and alerts and rarely question the bona fides.